查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1462569

STD 诊断市场规模- 按产品类型（仪器/分析仪、消耗品）、按测试类型（实验室和PoC 测试）、按疾病（梅毒、淋病、生殖器疱疹、HPV、HIV/AIDS）、按技术、按最终用途& 预测，2024 - 2032

STD Diagnostics Market Size - By Product Type (Instruments/Analyzers, Consumables), By Test Type (Laboratory & PoC Testing), By Disease (Syphilis, Gonorrhea, Genital Herpes, HPV, HIV/AIDS), By Technology, By End-use & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 389 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在 PCR 和快速检测解决方案等诊断技术进步的推动下，2024 年至 2032 年全球性病诊断市场规模将以 7.2% 的CAGR成长。这些进步提高了测试的准确性、速度和可访问性。此外，医疗服务的普及，包括现场检测和远距医疗，鼓励更多人寻求性病诊断。随着全球人口的成长和意识的提高，先进技术和增强的医疗保健服务的结合将显着扩大性病诊断产业，为疾病管理和预防提供重要工具。

例如，2023 年 3 月，BioPerfectus 推出了一系列用于 STD 诊断的 PCR 试剂盒。新推出的产品包括梅毒螺旋体即时PCR试剂盒和人类支原体即时PCR试剂盒，增强了其对性传染病的诊断解决方案。

性病诊断产业根据产品类型、测试类型、疾病、技术、最终用途和地区进行细分。

分子诊断领域将在 2032 年建立稳固的立足点，这归因于该领域的高精度、敏感性以及检测多种性传染病 (STD) 的能力。 PCR 和核酸扩增检验 (NAAT) 等分子检验可提供快速、准确的结果，这对于有效的治疗和预防至关重要。随着全球性病患病率的上升以及对可靠诊断的需求，分子诊断领域将主导市场，为疾病控制和管理提供重要工具。

到 2032 年，诊断实验室部分将在性病诊断市场中占据重要份额。作为主要检测中心，它们提供对于性传染病的早期检测和治疗至关重要的可近性和专业知识。随着人们越来越重视定期检测和筛检，诊断实验室将主导市场，在公共卫生措施和确保及时诊断和介入方面发挥至关重要的作用。

在意识提高、性病患病率上升和医疗基础设施改善的推动下，到 2032 年，亚太地区性病诊断产业将录得显着的CAGR。中国和印度等国家对诊断服务的需求旺盛，促进了市场成长。该地区对预防性医疗保健的关注和政府控制性传染病的倡议促成了这一趋势。随着人口的快速增长和医疗保健服务范围的扩大，亚太地区将成为全球性病诊断市场的重要贡献者，塑造其未来格局。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 性传染病发生率上升
      • 提高认识和筛检计划
      • 增加研究和开发活动
      • 性病诊断的技术进步
    • 产业陷阱与挑战
      • 耻辱与社会文化障碍
      • 严格的监管场景
  • 成长潜力分析
  • 技术景观
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：市场估计与预测：按产品类型，2018 年 - 2032 年

  • 主要趋势
  • 仪器/分析仪
    • 实验室设备
      • 热循环仪 - PCR
      • 侧向层析阅读器
      • 流式细胞仪
      • 吸光度酶标仪
      • 差分光散射机
      • 其他实验室设备
    • 护理点设备
      • 手机晶片（微流体+ICT）
      • 便携式/桌上型/快速诊断套件
  • 耗材

第 6 章：市场估计与预测：按测试类型，2018 年 - 2032 年

  • 主要趋势
  • 实验室测试
  • 护理点 (PoC) 测试

第 7 章：市场估计与预测：按疾病分类，2018 - 2032

  • 主要趋势
  • 沙眼衣原体/淋病奈瑟菌 (CT/NG)
  • 梅毒
  • 淋病
  • 生殖器疱疹（HSV I 和 HSV II）
  • HPV（人类乳突病毒）
  • HIV/AIDS（人类免疫缺乏病毒/后天免疫缺乏症候群）
  • 解脲支原体和支原体
  • 滴虫病
  • VZV（水痘带状疱疹病毒）
  • 其他疾病

第 8 章：市场估计与预测：按技术分类，2018 - 2032

  • 主要趋势
  • 免疫分析
  • 分子诊断
  • 其他技术

第 9 章：市场估计与预测：依最终用途，2018 年 - 2032 年

  • 主要趋势
  • 医院和诊所
  • 诊断实验室
  • 居家照护测试
  • 其他最终用户

第 10 章：市场估计与预测：按地区，2018 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 11 章：公司简介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • QIAGEN N.V.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc
简介目录
Product Code: 8292

Global STD Diagnostics Market size will grow at a 7.2% CAGR from 2024 to 2032, fueled by technological advancements in diagnostics such as PCR and rapid testing solutions. These advancements improve the accuracy, speed, and accessibility of testing. Additionally, improved access to healthcare services, including point-of-care testing and telemedicine, encourages more individuals to seek STD diagnostics. As the global population grows and awareness increases, the combination of advanced technology and enhanced healthcare access will significantly expand the STD diagnostics industry, providing crucial tools for disease management and prevention.

For instance, in March 2023, BioPerfectus introduced an expanded range of PCR kits for STD diagnostics. The newly launched products include the Treponema Pallidum Real-Time PCR Kit and the Mycoplasma Hominis Real-Time PCR Kit, enhancing their diagnostic solutions for sexually transmitted diseases.

The STD diagnostics industry is segmented based on product type, test type, disease, technology, end-use, and region.

The molecular diagnostics segment will establish a substantial foothold by 2032, attributed to the segment's high accuracy, sensitivity, and ability to detect a wide range of sexually transmitted diseases (STDs). Molecular tests, such as PCR and nucleic acid amplification tests (NAATs), offer rapid and precise results, which are crucial for effective treatment and prevention. With rising STD prevalence globally and the demand for reliable diagnostics, the molecular diagnostics segment will dominate the market, providing vital tools for disease control and management.

The diagnostic laboratories segment will garner a significant STD diagnostics market share by 2032. These labs are pivotal due to their comprehensive range of tests, including molecular and culture-based methods. As primary testing hubs, they offer accessibility and expertise crucial for the early detection and treatment of STDs. With a growing emphasis on regular testing and screening, diagnostic laboratories will dominate the market, playing a vital role in public health initiatives and ensuring timely diagnosis and intervention.

Asia Pacific STD diagnostics industry will record a noteworthy CAGR by 2032, propelled by increasing awareness, rising STD prevalence, and improving healthcare infrastructure. Countries like China and India witness high demand for diagnostic services, fostering market growth. The region's focus on preventive healthcare and government initiatives for STD control contribute to this trend. With a burgeoning population and expanding access to healthcare, Asia Pacific will emerge as a notable contributor to the global STD diagnostics market, shaping its future landscape.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast calculations
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of sexually transmitted diseases
      • 3.2.1.2 Growing awareness and screening programs
      • 3.2.1.3 Increasing research and development activities
      • 3.2.1.4 Technological advancements in STD diagnostics
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Stigma and sociocultural barriers
      • 3.2.2.2 Stringent regulatory scenario
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instrument/analyzers
    • 5.2.1 Laboratory devices
      • 5.2.1.1 Thermal cyclers - PCR
      • 5.2.1.2 Lateral flow readers
      • 5.2.1.3 Flow cytometers
      • 5.2.1.4 Absorbance microplate reader
      • 5.2.1.5 Differential light scattering machines
      • 5.2.1.6 Other laboratory devices
    • 5.2.2 Point of care devices
      • 5.2.2.1 Phone chips (Microfludics + ICT)
      • 5.2.2.2 Portable/bench top/rapid diagnostic kits
  • 5.3 Consumables

Chapter 6 Market Estimates and Forecast, By Test Type, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Laboratory testing
  • 6.3 Point of care (PoC) testing

Chapter 7 Market Estimates and Forecast, By Disease, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG)
  • 7.3 Syphilis
  • 7.4 Gonorrhea
  • 7.5 Genital herpes (HSV I & HSV II)
  • 7.6 HPV (Human papillomavirus)
  • 7.7 HIV/AIDS (Human immunodeficiency virus/ acquired immunodeficiency syndrome)
  • 7.8 Ureaplasma & mycoplasma
  • 7.9 Trichomoniasis
  • 7.10 VZV (Varicella zoster virus)
  • 7.11 Other diseases

Chapter 8 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Immunoassay
  • 8.3 Molecular diagnostics
  • 8.4 Other technologies

Chapter 9 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospitals & clinics
  • 9.3 Diagnostic laboratories
  • 9.4 Home care testing
  • 9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
    • 10.5.4 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 South Africa
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Abbott Laboratories
  • 11.2 Becton, Dickinson and Company
  • 11.3 bioMerieux SA
  • 11.4 Bio-Rad Laboratories, Inc.
  • 11.5 Danaher Corporation
  • 11.6 F. Hoffmann-La Roche Ltd
  • 11.7 Hologic, Inc.
  • 11.8 QIAGEN N.V.
  • 11.9 Seegene Inc.
  • 11.10 Siemens Healthineers AG
  • 11.11 Thermo Fisher Scientific Inc.
  • 11.12 Trinity Biotech plc